High efficacy of monomethoxypolyethylene glycolconjugated l-asparaginase (PEG2-ASP) in two patients with hematological malignancies

Leukemia Research

Volumn 15, Issue 6, 1991, Pages 525-530

  Kawashima, Kohei ^a   Takeshima, Hirotomo ^a   Higashi, Yasuyuki ^a,b   Hamaguchi, Motohiro ^a   Sugie, Hajime ^a,b   Imamura, Ikuo ^a,c   Wada, Hiroshi ^a,b  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yokkaichi City Hospital   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

asparagine; clearance; immunogenicity; leukemia; Polyethylene glycol conjugated l asparaginase; refractory

Indexed keywords

ALPHA INTERFERON; ASPARAGINASE; BACTERIAL ENZYME; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENOCITABINE; ETOPOSIDE; MACROGOL; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; VINCRISTINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG CONJUGATION; DRUG EFFICACY; DRUG MIXTURE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ESCHERICHIA COLI; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RELAPSE; SEPSIS; SIDE EFFECT;

ADULT; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CASE REPORT; FEMALE; HUMAN; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGE; POLYETHYLENE GLYCOLS;

EID: 0025900383     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(91)90064-Z     Document Type: Article

References (11)

1. l-asparaginase: clinical, biological, pharmacological and immunological studies
2. Favorable remission induction rate with twice weekly doses of asparaginase
3. Modification of E. colil-asparaginase with polyethylene glycol: disappearance of binding ability to anti-asparaginase serum
4. Reduction in immunogenicity and clearance rate of Escherichia colil-asparaginase by modification with monomethoxypolyethylene glycol
5. Increased antitumor activity of Escherichia colil-asparaginase by modification with monomethoxyethylene glycol
6. Evaluation of l-asparagine metabolism in animals and men
7. 2); Disappearance of binding ability towards anti-serum and retention of enzyme activity
8. Immune responses to polyethylene glycol modified l-asparaginase in mice
9. Fouragent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia
10. Unexpectedly high incidence of allergic reactions with high dose (HD) weekly asparaginase (ASP) consolidation (cons) therapy (Rx) in children with newly diagnosed non-T, non-B acute lymphoblastic leukemia (ALL): A Pediatric Oncology Group (POG) Study
11. The use of polyethylene glycol conjugated l-asparaginase (PEG-ASP) in pediatric patients with prior hypersensitivity to native l-asparaginase